We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

1czm

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1czm.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1czm.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1czm| PDB=1czm | SCENE= }}
{{STRUCTURE_1czm| PDB=1czm | SCENE= }}
-
'''DRUG-PROTEIN INTERACTIONS: STRUCTURE OF SULFONAMIDE DRUG COMPLEXED WITH HUMAN CARBONIC ANHYDRASE I'''
+
===DRUG-PROTEIN INTERACTIONS: STRUCTURE OF SULFONAMIDE DRUG COMPLEXED WITH HUMAN CARBONIC ANHYDRASE I===
-
==Overview==
+
<!--
-
N-unsubstituted sulfonamide drugs are widely used for opthalmic disorders. Inhibition of carbonic anhydrase enzyme is believed to be the chief reason for their therapeutic effects. Structures of three such sulfonamide drugs complexed to human carbonic anhydrase I enzyme (HCAI) refined crystallographically at 2 A resolution are reported here. The drug molecules are all bound in the active site of the enzyme, but among themselves show differences in the orientations of the sulfamido groups interacting with the essential zinc ion in the active site. The activity linked solvent molecule coordinated to zinc in the native enzyme is displaced by all the three sulfonamides. The active site loop of Leu198, Thr199 and His200 has been identified to be important for binding of the drug molecules due to their appreciable atomic displacements and intra-molecular hydrogen bonds arising out of their interactions with the sulfonamides. These interactions along with active site charge requirements are proposed to be responsible for the orientational differences of the sulfamido groups and also for differences in the inhibitory powers of the drugs. A hydrogen bond network involving solvent molecules and active site residues His200 and His67 amongst others in the native enzyme, is disrupted upon binding of methazolamide but not in the other two sulfonamides. This is the first crystallographic evidence of the possible involvement of His200 in the inhibition of HCAI. An important role of Thr199 in distinguishing between the substrate and inhibitor binding modes of HCO3- to the enzyme at high pH is also inferred.
+
The line below this paragraph, {{ABSTRACT_PUBMED_7932756}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 7932756 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_7932756}}
==About this Structure==
==About this Structure==
Line 28: Line 32:
[[Category: Protein-drug interaction]]
[[Category: Protein-drug interaction]]
[[Category: Sulfonamide]]
[[Category: Sulfonamide]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 13:16:48 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jun 30 21:52:48 2008''

Revision as of 18:52, 30 June 2008

Image:1czm.png

Template:STRUCTURE 1czm

DRUG-PROTEIN INTERACTIONS: STRUCTURE OF SULFONAMIDE DRUG COMPLEXED WITH HUMAN CARBONIC ANHYDRASE I

Template:ABSTRACT PUBMED 7932756

About this Structure

1CZM is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Drug-protein interactions. Refined structures of three sulfonamide drug complexes of human carbonic anhydrase I enzyme., Chakravarty S, Kannan KK, J Mol Biol. 1994 Oct 21;243(2):298-309. PMID:7932756

Page seeded by OCA on Mon Jun 30 21:52:48 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1czm"
Personal tools